Primerica, Inc. – Consensus ‘buy’ rating and 2.0% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Primerica, Inc. which can be found using ticker (PRI) now have 5 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $260.00 and $204.00 calculating the mean target price we have $230.60. Given that the stocks previous close was at $226.15 and the analysts are correct then we can expect a percentage increase in value of 2.0%. Also worth taking note is the 50 day moving average now sits at $211.64 while the 200 day moving average is $200.03. The total market capitalization for the company now stands at 7.91B. The stock price for the company is currently $225.66 USD

The potential market cap would be $8,061,336,054 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 17.39, revenue per share of $78.06 and a 2.99% return on assets.

Primerica, Inc. (Primerica) is a provider of financial products to middle-income households in the United States and Canada. The Company’s segments include Term Life Insurance, Investment and Savings Products, and Senior Health. The Company distributes the term life insurance products through its three-issuing life insurance company subsidiaries: Primerica Life Insurance Company (Primerica Life), National Benefit Life Insurance Company, and Primerica Life Insurance Company of Canada (Primerica Life Canada). The Investment and Savings Products segment includes retail and managed mutual funds and annuities distributed through licensed broker-dealer subsidiaries and includes segregated funds. It also distributes mutual fund and annuity products of several third-party companies in United States. The Company’s Senior Health segment consists of the distribution of Medicare-related insurance products underwritten by third-party health insurance carriers to eligible Medicare participants.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search